Oral Cavity Neoplasm

Observed

→ investigated in trials for

Cetuximabmonoclonal antibody

20 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal_antibody

19 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall_molecule

16 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

12 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall_molecule

11 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fluorouracilsmall_molecule

10 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinib Hydrochloridesmall_molecule

9 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall_molecule

9 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

6 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

5 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Celecoxibsmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cemiplimabmonoclonal antibody

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Hydroxyureasmall_molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Oral Cavity Neoplasm studied in …STUDIED_INderived10 of 425show all (up to 200)
→ studied in	NCT06589804Phase 3 · recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · condition mapped CURATED_BROADER · 425 trials mapped (155 active)	—	—	Oral Cavity Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07667400Phase 1/Phase 2 · not yet recruiting Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer · condition mapped ALIAS · 425 trials mapped (155 active)	—	—	Oral Cavity Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07844551Phase 2 · not yet recruiting ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC · condition mapped CURATED_BROADER · 425 trials mapped (155 active)	—	—	Oral Cavity Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05136196Phase 2 · recruiting BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · condition mapped CURATED_BROADER · 425 trials mapped (155 active)	—	—	Oral Cavity Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06980038Phase 2 · recruiting Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer · condition mapped ONTOLOGY_EXACT · 425 trials mapped (155 active)	—	—	Oral Cavity Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07124000recruiting DESTINY-PANTUMOUR04 · condition mapped ALIAS · 425 trials mapped (155 active)	—	—	Oral Cavity Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07836829not yet recruiting Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy · condition mapped CURATED_BROADER · 425 trials mapped (155 active)	—	—	Malignant Oral Cavity Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04671667Phase 2 · recruiting Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 425 trials mapped (155 active)	—	—	Oral Cavity Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05172245Phase 1 · recruiting Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer · condition mapped CURATED_BROADER · 425 trials mapped (155 active)	—	—	Oral Cavity Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07060261NA · recruiting Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 425 trials mapped (155 active)	—	—	Tonsillar Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →

Oral Cavity Neoplasm studied in …STUDIED_INderived10 of 425show all (up to 200)

→ studied in

NCT06589804Phase 3 · recruiting

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · condition mapped CURATED_BROADER · 425 trials mapped (155 active)

—

Observed

→ studied in

NCT07667400Phase 1/Phase 2 · not yet recruiting

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer · condition mapped ALIAS · 425 trials mapped (155 active)

—

Observed

→ studied in

NCT07844551Phase 2 · not yet recruiting

ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC · condition mapped CURATED_BROADER · 425 trials mapped (155 active)

—

Observed

→ studied in

NCT05136196Phase 2 · recruiting

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · condition mapped CURATED_BROADER · 425 trials mapped (155 active)

—

Observed

→ studied in

NCT06980038Phase 2 · recruiting

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer · condition mapped ONTOLOGY_EXACT · 425 trials mapped (155 active)

—

Observed

→ studied in

NCT07124000recruiting

DESTINY-PANTUMOUR04 · condition mapped ALIAS · 425 trials mapped (155 active)

—

Oral Cavity Carcinoma

Observed

Malignant Oral Cavity Neoplasm

→ studied in

NCT07836829not yet recruiting

Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy · condition mapped CURATED_BROADER · 425 trials mapped (155 active)

—

Observed

→ studied in

NCT04671667Phase 2 · recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 425 trials mapped (155 active)

—

Observed

→ studied in

NCT05172245Phase 1 · recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer · condition mapped CURATED_BROADER · 425 trials mapped (155 active)

—

Observed

Tonsillar Squamous Cell Carcinoma

→ studied in

NCT07060261NA · recruiting

Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 425 trials mapped (155 active)

—

Observed